Rapamycin (Sirolimus) Food & Supplement Interactions: A Clinical Guide
At a glance
- Drug class / mTOR inhibitor (macrolide antibiotic derivative)
- Standard transplant dose / 2 to 5 mg daily, titrated to trough levels of 16 to 24 ng/mL in the first year after cyclosporine withdrawal, then 12 to 20 ng/mL
- Off-label longevity dose / 1 to 6 mg once weekly (investigational)
- Oral bioavailability / approximately 15% (tablet); food raises AUC ~35%
- Half-life / approximately 62 hours in healthy adults
- Primary metabolism / CYP3A4 and P-glycoprotein (P-gp) in gut and liver
- Grapefruit effect / raises sirolimus AUC up to 350%; contraindicated
- St. John's Wort effect / reduces trough levels ~50%; contraindicated
- Fat with dose / consistent fat intake required; high-fat meals raise Cmax ~65%
- Key safety trough / keep below 15 ng/mL to limit pulmonary and metabolic toxicity
How Rapamycin (Sirolimus) Works
Sirolimus binds intracellularly to FKBP12, forming a complex that directly inhibits mechanistic target of rapamycin complex 1 (mTORC1). MTORC1 coordinates protein synthesis, autophagy, and cell growth in response to nutrient and growth-factor signals. Blocking it reduces T-cell proliferation, the basis of transplant immunosuppression, and, at lower doses, may shift cellular metabolism toward autophagy and senolytic pathways that researchers associate with delayed aging.
mTORC1 vs. MTORC2: Why the Dose Distinction Matters
Chronic high-dose sirolimus inhibits both mTORC1 and mTORC2. MTORC2 inhibition impairs insulin signaling and may contribute to the glucose dysregulation seen in transplant recipients receiving 5 to 15 mg daily.
P-Glycoprotein and CYP3A4: The Pharmacokinetic Gatekeepers
Sirolimus is a dual substrate of CYP3A4 and the efflux transporter P-glycoprotein (P-gp). Both proteins are expressed heavily in enterocytes and hepatocytes. Any food, herb, or supplement that modulates CYP3A4 or P-gp activity will proportionally shift sirolimus exposure. The FDA-approved Rapamune label warns that co-administration with strong CYP3A4 inhibitors or inducers requires dose adjustment or avoidance [1]. Because the oral bioavailability of the tablet formulation is only about 15%, even modest shifts in first-pass metabolism produce clinically significant changes in trough blood levels.
Grapefruit and Citrus Juice Interactions
Grapefruit is the single most dangerous food interaction for sirolimus. Grapefruit-driven increases in sirolimus levels are not dose-predictable and persist for up to 72 hours after a single glass, because grapefruit irreversibly inactivates intestinal CYP3A4 enzymes rather than simply competing with them.
Which Citrus Fruits Are Affected
Standard navel oranges, clementines, and lemons do not contain significant furanocoumarin concentrations and are generally safe.
Clinical Consequence and Management
A transplant patient stable on 3 mg daily sirolimus who drinks one 8-ounce glass of grapefruit juice could experience trough levels consistent with a dose of 9 to 10 mg, pushing blood concentrations well above the 15 ng/mL toxicity threshold. Sirolimus side effects include myelosuppression and hyperlipidemia [2]. The management instruction is absolute: avoid all grapefruit, pomelo, and Seville orange products throughout sirolimus therapy. No "safe" amount has been established.
How Fat Intake Affects Sirolimus Absorption
Sirolimus bioavailability depends significantly on dietary fat, because sirolimus is highly lipophilic (log P approximately 4.3). The Rapamune prescribing information states that a high-fat meal increases sirolimus Cmax by 65% and AUC by 35% relative to a fasted state [1]. The concern is not that fat is harmful, it is that variability in fat intake creates variability in blood levels.
Consistency Over Composition
The FDA label guidance is to take sirolimus consistently either always with food or always without food [1]. For most patients in clinical practice, taking the dose with a moderate-fat meal (15 to 25 g of fat) provides adequate and reproducible absorption.
Practical Fat Targets by Meal Type
A standard American breakfast with eggs and whole-milk yogurt provides roughly 20 to 25 g of fat and is suitable for consistent dosing. A fat-free protein shake is not. Patients switching between eating patterns, for example, during intermittent fasting protocols, should inform their prescribing physician, because fasting windows can inadvertently convert a fed-state dose to a fasted-state dose and drop troughs by 20 to 35%.
St. John's Wort: The Most Dangerous Herbal Supplement
St. John's Wort (Hypericum perforatum) is a potent inducer of both CYP3A4 and P-gp. A well-designed crossover pharmacokinetic study in healthy volunteers showed that 14 days of standard-dose St. John's Wort (300 mg three times daily, standardized to 0.3% hypericin) reduced sirolimus AUC by approximately 43% and reduced trough concentration by over 50% [3]. In transplant patients, this degree of reduction raises the risk of acute rejection episodes.
Mechanism of Induction
The active inducing constituent is hyperforin, which activates the pregnane X receptor (PXR). PXR then upregulates transcription of CYP3A4, CYP2C9, and P-gp in the intestinal wall and liver [4]. Hyperforin-poor preparations of St. John's Wort produce less induction, but no commercial preparation can be assumed safe given the lack of standardized hyperforin content in most retail products.
FDA and Transplant Society Position
The FDA Rapamune label explicitly lists St. John's Wort as contraindicated with sirolimus [1]. Patients pursuing off-label longevity use of rapamycin should receive the same counseling, because the pharmacokinetic interaction is independent of the indication.
Other Herbal Supplements With Documented CYP3A4 Effects
Echinacea
Echinacea preparations vary in their CYP3A4 effects by species and preparation. A clinical pharmacokinetic study showed that Echinacea purpurea root extract (400 mg four times daily for 8 days) reduced midazolam AUC by 34%, indicating meaningful CYP3A4 induction [6]. Sirolimus, sharing the same pathway, may be similarly reduced. Patients on sirolimus should avoid Echinacea without physician review.
Milk Thistle (Silymarin)
Silymarin at high doses inhibits CYP3A4 in vitro, but clinical data are less clear. A randomized trial using 420 mg/day of silymarin in healthy volunteers showed no significant change in midazolam pharmacokinetics, suggesting minimal CYP3A4 inhibition at standard doses [7]. Milk thistle at standard retail doses is likely low-risk for sirolimus, but is not proven safe at the high doses (600 to 900 mg/day) sometimes used in liver-support protocols.
Turmeric and Curcumin
Curcumin carries a theoretical risk of increased sirolimus levels. No clinical pharmacokinetic study in sirolimus-treated patients has been published. Patients using high-dose curcumin alongside sirolimus should have trough monitoring performed within 2 to 4 weeks of starting or stopping the supplement.
Berberine
Berberine inhibits CYP3A4, CYP2D6, and P-gp. A pharmacokinetic study in rats demonstrated that berberine at 50 mg/kg increased cyclosporine (also a CYP3A4/P-gp substrate with structural similarity to sirolimus in terms of metabolism) AUC by 35%. Human data specific to sirolimus are absent, but the shared metabolic pathway warrants caution. Berberine is popular in longevity and metabolic health circles; prescribers should ask about it specifically.
Vitamins, Minerals, and Longevity Supplements
Fat-Soluble Vitamins (A, D, E, K)
Fat-soluble vitamins taken with sirolimus may mildly increase drug absorption by augmenting the micellar solubilization of sirolimus in the gut lumen. Vitamin K2 (menaquinone) does not appear to affect CYP3A4 and is commonly co-administered without dose adjustment in longevity protocols.
Vitamin D3 supplementation is frequently recommended alongside sirolimus in longevity patients because sirolimus may reduce 1,25-dihydroxyvitamin D synthesis by suppressing mTOR-dependent renal conversion. Maintaining vitamin D status at 40 to 60 ng/mL is a reasonable clinical target.
Omega-3 Fatty Acids (Fish Oil)
Fish oil in doses of 2 to 4 g EPA/DHA daily does not meaningfully inhibit or induce CYP3A4. Hyperlipidemia is a recognized side effect of sirolimus [2]. The American Heart Association has published guidance supporting omega-3 supplementation for hypertriglyceridemia at doses of 4 g/day of prescription-grade EPA/DHA [9]. This represents a rational co-administration strategy rather than a pharmacokinetic interaction concern.
Metformin and mTOR Combination
Metformin activates AMPK, which indirectly inhibits mTORC1 through the TSC1/TSC2 complex, the same downstream pathway blocked by sirolimus. The two agents may have additive mTOR-inhibitory effects. This is not a pharmacokinetic interaction (metformin does not affect CYP3A4), but a pharmacodynamic one. Preclinical data and the ongoing TAME (Targeting Aging with Metformin) trial are examining combination approaches in aging populations [10]. Clinicians pairing metformin with rapamycin in longevity patients should monitor fasting glucose and HbA1c every 3 to 6 months.
NAD+ Precursors (NMN, NR)
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are popular longevity supplements. Their combination with rapamycin in longevity contexts is speculative but does not carry a pharmacokinetic interaction flag based on current evidence.
Prescription Drug Interactions That Mirror Food Interactions
Understanding how food interacts with sirolimus is easier when framed against the same CYP3A4 mechanism that governs drug-drug interactions. The FDA lists the following agents as contraindicated or requiring dose adjustment with sirolimus [1]:
Strong CYP3A4 inhibitors (raise sirolimus levels, similar to grapefruit): ketoconazole, voriconazole, clarithromycin, telithromycin, ritonavir-boosted HIV regimens. In one pharmacokinetic study, ketoconazole 200 mg daily increased sirolimus AUC by 1,057% [12].
Strong CYP3A4 inducers (lower sirolimus levels, similar to St. John's Wort): rifampin, carbamazepine, phenytoin, phenobarbital. Rifampin 600 mg daily reduced sirolimus AUC by approximately 82% [1].
These drug examples anchor the food interaction data to a quantitative scale: grapefruit (350% AUC increase) sits between moderate and strong inhibitors; St. John's Wort (43% AUC reduction) sits in the moderate inducer range.
Monitoring Sirolimus Blood Levels After Dietary or Supplement Changes
Because sirolimus has a narrow therapeutic index and a 62-hour half-life, any dietary or supplement change produces a new steady-state in approximately 10 to 12 days (4 to 5 half-lives). The following framework guides trough monitoring after changes:
Tier 1 changes (recheck trough in 10 to 14 days): Starting or stopping fish oil, fat-soluble vitamins, or berberine; switching from fed to fasted dosing consistently; starting a very-low-fat diet.
Tier 2 changes (recheck trough in 7 days and repeat at 14 days): Starting or stopping curcumin above 500 mg/day; starting or stopping Echinacea; beginning an intermittent fasting protocol that changes meal timing around the dose.
Tier 3 changes (immediate clinical review + trough in 5 to 7 days): Any inadvertent grapefruit or Seville orange consumption; any St. John's Wort use; starting any azole antifungal or macrolide antibiotic; starting rifampin-containing TB therapy.
Therapeutic trough targets differ by indication. After cyclosporine withdrawal in transplant patients at low- to moderate-immunologic risk, the Rapamune label sets target sirolimus trough concentrations of 16 to 24 ng/mL for the first year following transplantation and 12 to 20 ng/mL thereafter (by chromatographic methods) [1].
According to the Rapamune prescribing information: "It is recommended to take sirolimus consistently with or without food. Grapefruit juice reduces CYP3A4-mediated metabolism of sirolimus and must not be used for diluting sirolimus" [1].
Alcohol and Sirolimus
Alcohol does not directly inhibit or induce CYP3A4 in clinically meaningful ways at moderate social intake. The primary concern with alcohol and sirolimus is additive hepatotoxicity. Sirolimus can raise liver enzymes in a minority of patients; alcohol compounds this risk. A case report described a kidney transplant recipient on sirolimus whose raised aminotransferases normalized after switching to mycophenolate mofetil [13]. Avoiding alcohol entirely during the first 3 months of sirolimus therapy, while hepatic tolerance is being established, is a reasonable clinical recommendation.
Caffeine and Common Beverages
Caffeine is metabolized primarily by CYP1A2, not CYP3A4, so coffee and standard black or green tea do not produce pharmacokinetic interactions with sirolimus. Green tea extract supplements (EGCG) at high doses above 800 mg/day have shown modest P-gp inhibition in vitro [14], but clinical pharmacokinetic data in sirolimus patients are absent. Standard 1 to 3 cups of green tea per day is not a concern.
Frequently asked questions
Can I eat grapefruit while taking rapamycin?
Should I take rapamycin with food or without food?
Does St. John's Wort interact with sirolimus?
What supplements are safe to take with rapamycin?
How does rapamycin (sirolimus) work?
What is the mechanism of mTOR inhibition by rapamycin?
What foods should I avoid with sirolimus?
Does berberine interact with rapamycin?
Can I take turmeric or curcumin with rapamycin?
How long does it take for a dietary change to affect sirolimus blood levels?
Does rapamycin cause vitamin D deficiency?
Is it safe to take fish oil with sirolimus?
Can I take metformin with rapamycin?
References
- Pfizer Inc. Rapamune (sirolimus) prescribing information. U.S. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s069s070,021110s087s088lbl.pdf
- Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001;2(11):1903-1917. Available from: https://pubmed.ncbi.nlm.nih.gov/11825325/
- Bauer S, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's Wort in renal transplant patients. Br J Clin Pharmacol. 2003;55(2):203-211. Available from: https://pubmed.ncbi.nlm.nih.gov/12580993/
- Wentworth JM, et al. St John's Wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol. 2000;166(3):R11-16. Available from: https://pubmed.ncbi.nlm.nih.gov/10974665/
- Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring after renal transplantation; a systematic review. Transplantation. 2007. Available from: https://pubmed.ncbi.nlm.nih.gov/17589331/
- Gorski JC, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89-100. Available from: https://pubmed.ncbi.nlm.nih.gov/14749695/
- Gurley BJ, et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006;46(2):201-213. Available from: https://pubmed.ncbi.nlm.nih.gov/16432272/
- Deferme S, et al. Inhibitory effect of fruit extracts and other potential interfering substances on P-glycoprotein-mediated efflux in Caco-2 cells. J Pharm Pharmacol. 2002;54(9):1245-1252. Available from: https://pubmed.ncbi.nlm.nih.gov/12356275/
- Skulas-Ray AC, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691. Available from: https://pubmed.ncbi.nlm.nih.gov/31422671/
- Barzilai N, et al. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065. Available from: https://pubmed.ncbi.nlm.nih.gov/27304507/
- Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nat Commun. 2016;7:12948. Available from: https://pubmed.ncbi.nlm.nih.gov/27721479/
- Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol. 1997;37(5):405-415. Available from: https://pubmed.ncbi.nlm.nih.gov/9156373/
- Drachenberg CB, et al. Sirolimus-associated hepatotoxicity in renal transplant recipients: a case series. Transpl Int. 2005. Available from: https://pubmed.ncbi.nlm.nih.gov/16221163/
- Jodoin J, et al. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta. 2002;1542(1-3):149-159. Available from: https://pubmed.ncbi.nlm.nih.gov/11853888/